Monoclonal antibodies specifically target ligation of vascular tissues 1 and 2 in receivers of the second report of the Third Assessment Report； Parts； Nucleic acid molecular coding； Vectors； Huesped cells； Preparation methods； Drug synthesis to understand this point； and Inhibition of non-communicable angioplasty Like cancer.
Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.ANTICUERPO MONOCLONAL AISLADO ESPECIFICO CONTRA LOS LIGANDOS ANGIOPOYETINA 1 Y 2 DEL RECEPTOR TIE 2； FRAGMENTO DEL MISMO； MOLECULA DE ACIDO NUCLEICO QUE LO CODIFICA； VECTOR； CELULA HUESPED； METODO DE PREPARACION； COMPOSICION FARMACEUTICA QUE LO COMPRENDE； Y SU USO PARA INHIBIR LA ANGIOGENESIS NO DESEADA TAL COMO CANCER.
